B-ALL accounts for approximately 85% of pediatric cases and is characterized by a variety of genetic abnormalities such as the Philadelphia chromosome, CRLF2 rearrangements, and KMT2A rearrangements, each influencing prognosis and therapeutic approaches [10,16]. This evidence concerns the gene KMT2A and acute lymphoblastic leukemia.